Sino Biopharm and Boehringer Ingelheim Reach US$7 Billion Licensing Agreement
Start here
On 5 November 2026, Sino Biopharm announced that it had entered into a strategic option and licence agreement with Boehringer Ingelheim covering 6 preclinical programmes involving antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), originating from LaNova Medicines and Beijing Tide. Under the agreement, Sino Biopharm will receive US$358 million in upfront and near-term payments and is entitled to potential milestone payments totalling US$7 billion, as well as tiered double-digit royalties on future sales. The reports did not mention any further approval or implementation progress of the agreement.
Generated by AI from reporting · updated 2 hours ago
Reporting timeline
Follow the reports to explore different aspects of the story.
- 明報·每日經濟Sino Biopharm Partners with Boehringer Ingelheim on Projects with Potential Total Value of US$7 Billion
Sino Biopharm has entered into a strategic option and licence agreement with Boehringer Ingelheim covering 6 preclinical projects involving antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), originating from LaNova Medicines and Beijing Tide. Sino Biopharm will receive US$358 million in upfront and near-term payments and is entitled to potential milestone payments totalling US$7 billion, as well as tiered double-digit royalties on future sales.
Activity over time for this story
There are not enough continuous observations to draw a trend yet.